Benchmark Holdings PLC Corporate Call Transcript
Good morning, and welcome to all of you to this investor call.
As you know, Friday became a very important day for us in Benchmark since we received the marketing authorization from the Norwegian Medicines Agency on Ectosan Vet. It came in on Friday afternoon, and we, of course, issued an RNS, an RNS that is rather comprehensive and should be, to a large extent, self-explanatory. But since this is a very important event in a main project for Benchmark, we figured it could be very useful to have this call in order for you as investors to pose questions to us if you have.
But before moving into the Q&A we would like to underline a couple of main points, so if you can move to Slide 2. To receive the marketing authorization is a very significant step and a breakthrough for Benchmark, something that we have been working incredibly hard to achieve for a very long time. And we are, of course, very excited that we have managed to achieve this. The fact that we have received the marketing authorization means that we are allowed to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
